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Functional inactivation of the tumour suppressor protein p16
INK4a constitutes a key event in the multistep process of pancreatic
ductal cell transformation. However, the significance of p16 inactivation for complex and tissue-specific aspects of pancreatic cancer
progression, such as angiogenesis and metastasis, is less understood. Here, we inducibly re-expressed p16 in vivo in an orthotopic
model of pancreatic cancer and examined the impact on these clinically relevant aspects of pancreatic cancer tumour biology.
Consistent with previous work in subcutaneous xenograft models, we found p16 capable of reducing primary tumour growth. In
addition, p16 restitution resulted in a marked reduction of tumour angiogenesis, largely accounted for by a p16-dependent inhibition
of lymphangiogenesis. In excellent agreement with the antilymphangiogenic effect, re-expression of p16 almost completely prevented
lymph node metastases of MiaPaca-2 pancreatic tumours. To our knowledge, this is the first report that experimentally links the
tumour suppressor p16 to the process of lymphangiogenesis.
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At the time of diagnosis, most patients with pancreatic cancer
require systemic therapy as invasive growth and metastatic spread
occur early in the course of the disease (Hezel et al, 2006; Chu et al,
2007). Unfortunately, pancreatic cancer has proven remarkably
resistant to current systemic treatment modalities including
chemo- and radiotherapies (Xiong et al, 2006), suggesting a
unique combination of molecular alterations accounts for this
highly unfavourable biological profile. Several molecular altera-
tions were identified, such that pancreatic cancer is now perceived
as a genetic disease characterised by the sequence of onco-
genic K-ras activation, inactivation of the tumour suppressor
p16
INK4a, and inactivation of the tumour suppressors p53 and/or
DPC4. Most pancreatic cancer cells harbour a combination of 3–4
of the alterations (Rozenblum et al, 1997). Activation of K-ras in
virtually all samples of ductal pancreatic adenocarcinoma marks
the initiation of the multistep transformation process, but
functional inactivation of p16
INK4a in up to 90% of cases ranks
second in frequency (Caldas et al, 1994; Hezel et al, 2006).
p16 was discovered as a tumour suppressor and an inhibitor of
cyclin D-associated CDK complexes. The main biological function
of p16
INK4a indeed involves the regulation of cell cycle progression
at the G1/S boundary (Serrano et al, 1993). Additional biological
functions in processes such as cell senescence, invasive growth,
cell spreading, apoptosis, anoikis and angiogenesis were
subsequently reported. p16
INK4a-deficient mice present with
increased incidence of spontaneous and carcinogen-induced
cancers (Kim and Sharpless, 2006). More recently p16
INK4a
was associated with the clonal evolution of epidermal cells such
that inactivation of p16 maintained epidermal cells in the stem
cell compartment (Maurelli et al, 2006). In extension of these
findings, knockout models have unveiled an age-dependent,
tissue-specific function of p16 in limiting stem cell renewal
(Kim and Sharpless, 2006).
A central role of p16 in pancreatic carcinogenesis was
firmly established from the analysis of clinical specimens
and corroborated by subsequent genetic studies in mice, as
tissue-specific oncogenic activation of K-ras in Ink4a/ARF
 /  or
Ink4A
 / /ARF
þ/þ mice, but not in wild-type mice resulted in
pancreatic ductal adenocarcinoma (Aguirre et al, 2003; Bardeesy
et al, 2006). Also, tumour formation in the pancreas of p53
 / 
mice overexpressing TGF-a was accompanied by deletion of the
INK4a locus (Wagner et al, 2001). Owing to the tumour suppressor
function, p16 reconstitution represents an appealing therapeutic
approach. Accordingly, the biological effects following reconstitu-
ting p16 function in vitro have been extensively characterised
(Rocco and Sidransky, 2001) and p16 was shown to inhibit growth
of subcutaneous xenografts (Spillare et al, 1996; Rocco et al, 1998).
However, little is known about the consequences of p16
re-expression for more complex aspects of tumour biology such
as vascularisation and metastatic spread.
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subcutaneous approach, which fails to provide a representative
microenvironment (Killion et al, 1998). Therefore, we aimed to
study the effects of p16 in the more physiologic microenvironment
of an orthotopic xenograft model. We furthermore, were
concerned about epigenetic changes that might accompany the
selection of clones with stable overexpression of p16. Therefore, an
inducible expression system seemed mandatory.
In consequence, we combined an inducible expression system in
pancreatic cancer cells with an orthotopic tumour model to study
the effects of p16 reconstitution on tumour formation, growth,
invasion, angiogenesis and metastasis in a representative in vivo
model.
MATERIALS AND METHODS
Cell culture
MiaPaCa-2 cells (ATCC, Manassas, VA, USA) were grown as
subconfluent monolayers in DMEM (Invitrogen, Berlin, Germany)
containing 10% FCS, 2mmoll
 1 glutamine and 100Uml
 1
penicillin/streptomycin (Biochrom, Berlin, Germany) at 371Ci n
95% air and 5% CO2.
Cloning and generation of the tetracycline inducible cell
line MiaPaCa-2-TREx-p16
The components of the TREx system (Invitrogen, Berlin, Germany)
include the regulatory plasmid (pcDNA6/TR), the inducible
plasmid (pcDNA4/TO) and a luciferase encoding reporter plasmid
(pcDNA4/TO-Luc). MiaPaCa-2 cells were transfected (Effectene,
Quiagen, Hilden, Germany) with pcDNA6/TR and stable clones
(MiaPaCa-2-TREx) were selected by blasticidin (5mgml
 1). TetR
promoter activation was achieved with 1mgml
 1 Doxycycline
(Sigma Chemical Co., Deisenhofen, Germany) and responsiveness
was evaluated by transient transfection with pcDNA4/TO-Luc
followed by a luciferase assay (Promega, Mannheim, Germany).
The full length cDNA of p16 was subcloned into pcDNA4/TO using
restriction enzymes HindIII and KpnI (Invitrogen, Berlin, Ger-
many), resulting in pcDNA4/TO-p16. MiaPaCa-2-TREx-p16 cells
were obtained through transfection of pcDNA4/TO-p16 into the
MiaPaCa-2-TREx cells and selection with zeozin (0.5mgml
 1)/
blasticidin (5mgml
 1) (Invitrogen, Berlin, Germany).
Western blotting
Cell lysates were prepared and blotted as described (Plath et al,
2000). Membranes were blocked and reacted overnight at 41C with
monoclonal antibodies (anti-p16
INK4a (1:1000) BD Pharmingen,
Heidelberg, Germany), anti-pRB (1:1000) BD Pharmingen), anti-
VEGF-C (Zytomed, Berlin, Germany) or VEGF-D (von Marschall
et al, 2005), followed by appropriate secondary antibodies.
Immunoreactive bands were visualised using an enhanced luminol
reagent (Perkin-Elmer Life Science, Boston, USA).
Cell proliferation (AlamarBlue assay)
Alamar Blue dye was purchased from Biosource International Inc.
(Camarillo, CA, USA) and the manufacturer’s instructions were
followed to complete the assay (Ahmed et al, 1994; Nakayama et al,
1997).
Anchorage-independent growth
For evaluation of anchorage-independent growth, 10
3 cells were
diluted in 1ml methylcellulose/agar mixture resolved in Iscove’s
medium (Invitrogen, Berlin, Germany) supplemented with 27%
fetal bovine serum (HyClone, Utah, USA). Cells were plated in
triplicate on 3-cm dishes and incubated for 10 days. Colonies
containing 420 cells were counted with an inverted light
microscope.
Animals
Female NMRI nude mice were purchased from Taconic M&B,
Denmark. The studies were performed in accordance with a
protocol approved by the regional animal research committee the
‘Landesamt fu ¨r Gesundheit und Soziales Berlin Nr. A0136/01’. The
in vivo procedures were in compliance with the UKCCCR
guidelines.
Orthotopic implantation
Orthotopic implantation was carried out when mice were
about 7–8 weeks old. General anaesthesia was performed by
intraperitoneal injection of a mixture of ketamine (100mgkg
 1)
and xylazine (20mgkg
 1). In 2 12 animals, 1 10
6 MiaPaca-
TREx-p16 cells were injected into the head of the pancreas to
visibly infiltrate the pancreatic tissue (Alves et al, 2001). In
two mice the implantation failed due to a loss of cells into the
abdomen during the procedure. Therefore the mice have to be
killed. In successful implanted animals (n¼22) p16 induction was
started one day after tumour cell inoculation by adding
doxycycline (2mgml
 1) plus 2% sucrose to the drinking
water (n¼11 mice), whereas control animals received 2%
sucrose alone (n¼11 mice). All animals tolerated the procedure
well. After implantation, mice were inspected daily for body weight
loss, general condition, and tumour formation in the peritoneal
cavity (abdominal distension). At the time of killing, primary
tumours were removed and weighted. Tumour volume was
calculated using the formula length width depth p/6.
Mesenterial and liver hilus lymph nodes were routinely collected
for further examination.
Immunohistochemistry
Primary tumours and lymph nodes were analysed by standard
immunoperoxidase staining procedure. Briefly, 7mm thick cryo-
sections were fixed in 4% paraformaldehyde/PBS, pH 7.0, for
20min at room temperature (RT), treated with 0.3% H2O2
for 10min and incubated overnight at 41C with anti-human
p16
INK4a (NEOMarkers, CA, USA) or 1h at RT with antibodies to
mouse LYVE-1 (Relia Tech, Braunschweig, Germany), mouse
CD31 (BD Pharmingen, Heidelberg, Germany) or human pan-
cytokeratin-HRP (Santa Cruz Biotechnology, CA, USA) (1:50)
followed by incubation with a biotinylated secondary antibody.
Immunoreactivity was detected with an avidin–biotin complex
method (Vectastain Elite ABC kit) and AEC substrate. Sections
were counterstained with hematoxylin.
Angiogenesis and lymphangiogenesis
For quantitation of microvessel density (MVD) and lymphatic
vessel density, respectively, the average numbers of CD31 and
LYVE-1 positive vessels from three areas of maximal vascular
density (vascular hotspots) were counted (Weidner, 1995).
Statistical analysis
Data were analysed by t-test and Fishers exact test using Graph Pad
statistical software (GraphPad Software Inc., San diego, CA, USA).
Differences were considered significant at Po0.05.
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Generation of MiaPaCa-2 pancreatic cancer cells with
doxycycline-inducible expression of p16
To obtain inducible p16-expression in pancreatic cancer cells
in vivo, a modified tetracycline-inducible expression system
(Gossen et al, 1995; Yao et al, 1998) was chosen, which permits
in vivo gene induction by adding tetracycline to the drinking
water.
Initially, we established MiaPaCa-2 cells with stable integration
of pcDNA6/TR, which encodes the tet-repressor. Clones with
abundant expression were subsequently identified in transient
cotransfections with a tet-repressor-regulated luciferase reporter
construct (data not shown). A clone with approximately 10-fold
induction (clone MiaPaCa-TREx-10) was identified and utilised in
a second transfection to introduce pcDNA4/TO-p16, which
encodes p16 under the control of a tet-responsive promoter, such
that tetracycline or doxycycline induce p16 expression. Western
Blot analysis of multiple independent stable transfected clones
revealed variable responses to doxycycline, ranging from no effect
(clone number 11) to high expression of p16 associated with
varying degrees of promoter leakage (Figure 1A, clone 13, 14). We
chose two clones (number 13 and 16, not shown) for further
studies, as these clones provided pronounced induction of p16
expression with minimal ‘leakage’ of basal p16 expression in the
absence of doxycycline. The latter was of particular importance to
ascertain that cells maintained the characteristics of parental
MiaPaca-2 cells under control conditions. More detailed analyses
revealed that p16-induction was rapid in onset, resulting in
substantial amount of p16 at 24h followed by a modest further
increase up to 96h. These analyses also confirmed the negligible
background expression in the absence of Dox treatment.
Because p16 has been shown to suppress pRB expression
in vitro, we hypothesised that pRB expression could provide a
simple indicator for the functional integrity of the p16 molecule
expressed from the Dox-regulated vector system. Indeed, induc-
tion of p16 in MiaPaCa-2 TREx-p16 cells reduced pRB content,
indicating that a functionally intact p16 molecule was induced
(Figure 1B).
Effects of doxycycline-induced p16 expression on growth
of MiaPaCa-2-TREx cells in vitro
Effects of p16 on proliferation of MiaPaCa-2 cells in vitro were
studied next. A time-dependent increase in cell numbers was
observed both in the presence and absence of Dox. Although a
trend towards a reduction of cell numbers was observed in
Dox-treated cultures, this effect did not reach statistical
significance (Figure 2A).
In our previous studies, p16 restitution in Capan-1 cells
abrogated tumorigenicity in vivo (Plath et al, 2000), which was
reflected by a severe reduction of colony formation in vitro.W e
therefore examined the impact of p16 induction on colony
formation of MiaPaCa-2 cells and observed a B30% decrease
following addition of Dox (Figure 2B). Comparable results were
obtained with MiaPaCa-2-TREx-p16 clone no. 16 (data not shown).
Taken together, inducible p16 expression elicited minor direct
growth inhibitory effects on MiaPaCa-2 cells in vitro. Thus, this
cell model seemed ideally suited to provide information about the
context driven effects of p16 on tumour growth.
Induction of p16 inhibits primary tumour growth of
orthotopic MiaPaCa-2 xenografts
As we intended to study the inducible MiaPaCa-2-TREx-p16 cell
system in the orthotopic context, we initially had to confirm the
0 h 24 h 48 h 72 h  96 h
p16
pRb
16 kDa
116 kDa
–– +– +– +– ++Dox
p16 16 kDa
10 11 12 13 14
Clone number
+ Dox
Figure 1 Generation MiaPaCa-2-TREx–p16 cells with doxycyclin-
inducible expression of p16. (A) The plasmids pcDNA6/TR and
pcDNA4/TO-p16 were sequentially transfected into p16-deficient MiaPa-
Ca-2 cells and clones with inducible expression of p16 were selected
(MiaPaca-2-TREx-p16). For each of the zeozine-resistant MiaPaCa-2-TREx-
p16 clone, cells were grown for 48h in the presence (þDox) or absence
( Dox) of 1mgml
 1 doxycycline. The expression of p16 protein was
analysed by western blotting. The clones with the highest p16 induction
and lowest basal expression were further analysed, for example clone 13.
(B) Time course of doxycycline-induced p16 expression. Cells were
cultured for 96h in the presence or absence of doxycycline and each 24h,
lysates were prepared for western blot analysis of p16 (upper panel) and
pRB (lower panel). Equal amounts of protein (20mg) were separated on
sodium dodecyl sulphate polyacrylamide gel electrophoresis.
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Figure 2 Effects of doxycycline-induced p16 expression on growth of
MiaPaCa-2-TREx cells in vitro.( A) Time-dependent proliferation
of MiaPaCa-2-TREx-p16 cells in the presence and absence of Dox as
determined based on Alamar Blue assay. Every 24h alamar blue dye was
applied to the media of the cells and fluorescence was determined as an
indirect measurement of cell numbers. (B) Effects of p16 expression on
anchorage-independent growth of MiaPaCa-2-TREx-p16/13 cells.
Anchorage-independent growth was evaluated based on soft agar colony
formation. 10
3 cells were seeded out in a methylcellulose/agar mixture
and incubated in the presence (þDox) or absence ( Dox) of doxycycline
for 10 days. Vital colonies were counted. Values shown are the
mean±s.e.m. for each group (þ/ Dox) of three independent
experiments.
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extensive local tumour growth with invasion of adjacent organs
exactly as parental MiaPaca-2 cells. Furthermore, Dox treatment of
mice carrying MiaPaca-2-TREx cells was well tolerated and did not
significantly reduce primary tumour weight, suggesting that Dox
treatment per se would not confound growth regulatory effects of
p16 induction (data not shown).
We then proceeded to induce p16 expression in tumour bearing
mice as described in material and methods. After 8 weeks mice
were killed and primary tumours were removed to determine
volume and weight. Representative pictures of the abdominal situs
in mice from control ( Dox) and treatment groups (þDox) at the
time of autopsy are presented in Figure 3A. Mean tumour weight
and volume of primary tumours were lower in treated animals, but
a conspicuous variation of values in the treatment group precluded
statistical significance. We hypothesised that this variability might
reflect differences in the level of p16 induction and accordingly
examined p16 expression by immunohistochemistry. Successful
in vivo induction was evident in 6 out of 11 mice with MiaPaCa-2-
TREx-p16 orthotopic tumours (Figure 3B). p16 was absent in 8 out
of 11 mice from the control group, but a weak signal was obtained
in the remaining three control tumours, possibly due to promoter
leakage. Based on these results, we excluded tumours of animals
without immunohistological corroboration of p16 expression or
absence from the analysis. When weight and volume from the
tumours with confirmed re-expression of p16 were compared to
values from controls, a significant reduction by 60 and 52%,
respectively, was noted (Figure 3C). Furthermore, several control
tumours, but none with p16 induction invaded into surrounding
tissues as stomach and duodenum (data not shown). Altogether,
re-expression of p16 in pancreatic cancer cells substantially
reduced orthotopic tumour growth in vivo and thus surpassed
the growth inhibitory effects in vitro.
Induction of p16 expression reduced angiogenesis in
orthotopic MiaPaCa-2 pancreatic carcinoma
Growth inhibition may have resulted from direct antiproliferative
or proapoptotic effects of p16 in the tumour cells or from indirect
mechanisms. As vascularisation is a prerequisite for tumour
growth, we examined whether p16 affected angiogenesis. Cryo-
sections of the primary tumours were stained with CD31
(Figure 4A) to detect endothelial cells and average MVD was
determined. MVD values in the control group ranged from 38 to
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Figure 3 Induction of p16 expression reduced primary tumour growth in orthotopic MiaPaCa-2 pancreatic carcinomas. Pancreatic MiaPaCa-2-TREx-p16
cells were grown orthotopically in the pancreas of mice treated with or without Dox as indicated. At the end of the treatment (8 weeks) tumour volumes
and weights were calculated. (A) Open situ of representative mice from the control ( Dox) and treatment group (þDox). (B) Confirmation of p16
induction in vivo. Primary tumours were analysed for p16 expression by immunohistochemistry using an antibody against p16. An example of p16 expression
in a small tumour in the treatment group is shown on the right panel, with detection of p16 protein in the nucleus and in the cytoplasm of tumour cells. In
contrast, no signal was obtained in control tumours ( Dox) (images at  20 magnification). (C) Summary of primary tumour weights (left) and volumes
(right) from Dox-treated animals. Data represent mean±s.e.m. for each group. *Po0.05.
p16 inhibits lymphangiogenesis
P Schulz et al
113
British Journal of Cancer (2008) 99(1), 110–117 & 2008 Cancer Research UK
T
r
a
n
s
l
a
t
i
o
n
a
l
T
h
e
r
a
p
e
u
t
i
c
s76, indicating that the MiaPaca-2 tumours were well vascularised.
Induction of p16 significantly reduced the MVD (35 vs 51,
P¼0.0123, Figure 4B). It is noteworthy that tumour size per se did
not correlate with MVD (Figure 4C), indicating that reduced MVD
observed in the treatment group likely reflected a specific
biological effect of p16 restitution.
Induction of p16 expression reduced lymphangiogenesis in
orthotopic MiaPaCa-2 pancreatic carcinoma
Owing to the reduction in MVD apparent from CD 31 staining
could result from an inhibition of either hem- or lymphangio-
genesis, the latter was separately determined based on the immuno-
staining with LYVE-1 (Figure 5A), an antibody that recognises the
hyaloronan receptor-1 of lymphatic vessels. Tumours with
confirmed p16 induction (þDox) contained less Lyve-1 positive
lymphatic vessels than control tumours (33% reduction,
P¼0.0299, Figure 5B). Similar to MVD, LVD did not correlate
with tumour size (Figure 5C). Thus, re-expression of p16 inhibited
lymphangiogenesis.
Induction of p16 expression reduced metastasis in
orthotopic MiaPaCa-2 pancreatic carcinoma
As tumour size, tumour angiogenesis and lymphangiogenesis are
important determinants of metastatic tumour progression,
metastasis formation of orthotopic MiaPaCa-2 tumours was
examined. On macroscopic inspection the abdominal organs
and lungs of either treatment or control group were tumour-free.
At the microscopic level however (Figure 6A), human
MiaPaCa-2-TREx-p16 cells were detected in liver hilus lymph
nodes of 10 out of 11 mice in the control group (91%), using an
anti-human pan-cytokeratin antibody (Figure 6A and B). In
contrast, hilar lymph node metastases had occurred in only one
of the tumours with re-expression of p16 (Figure 6B). Mesenterial
lymph nodes had not been invaded by metastatic cells in any of the
mice (data not shown).
As lymphatic spread was the prevalent mode of metastasis in
MiaPaca-2-TREx-p16 tumours, we compared the LVDs in tumours
from mice with (Nþ) or without lymph node infiltration (N )
(Figure 6C). A significant difference in LVDs was observed
between groups, suggesting that reduced lymphvascularisation in
tumours with p16 expression had impaired their capacity for
metastatic spread. In contrast, no difference was found with
respect to hemangiogenesis as calculated from the difference of
MVD and LVD (data not shown).
DISCUSSION
Functional inactivation of the tumour suppressor p16 marks a key
event in pancreatic carcinogenesis. Conversely, reconstitution of
the biological action of p16 provides an attractive therapeutic
approach. Here, we addressed the consequences of p16
re-expression in MiaPaca-2 pancreatic cancer cells in vivo in the
orthotopic tissue context. Consistent with previous work in
subcutaneous xenograft models (Spillare et al, 1996; Harada
et al, 1999; Hosotani et al, 2002), we found p16 capable of reducing
primary tumour growth. In addition, p16 restitution resulted in a
marked reduction of tumour angiogenesis, largely accounted for
by a p16-dependent inhibition of lymphangiogenesis. In excellent
agreement with the antilymphangiogenic effect, re-expression of
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Figure 4 Induction of p16 expression reduced angiogenesis in orthotopic MiaPaCa-2 pancreatic carcinomas. Cryosections of the tumours from control
( Dox) and treatment group (þDox) were stained with the endothelial marker CD31. To determine microvessel density (MVD) CD31-expressing vessels
were quantitated from hotspot areas, as described in Materials and methods. (A) Shown are representative CD31 stainings from a ( Dox) and a (þDox)
tumour (B) and quantitative evaluation of the results, *Po0.05. (images at  20 magnification) (C) Relationship of MVD and tumour weight. MVD values
from both groups (þ/ Dox) were plotted against the respective tumour weight to assess a potential correlation of both parameters. The distribution
shows no correlation.
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sp16 prevented lymph node metastases of MiaPaca-2 pancreatic
cancer cells. To our knowledge, this is the first report that
experimentally links p16 to the process of lymphangiogenesis.
The restitution of p16 function remains an attractive therapeutic
approach and a focus of drug development (Senderowicz and
Sausville, 2000; Hosotani et al, 2002; Kondo et al, 2004).
So far, little is known about the consequences of p16
re-expression for more complex aspects of organ-specific tumour
growth, which we focussed on in the current study. To this end, we
combined a tetracycline-inducible expression system with an
orthotopic approach, which allowed to overcome several potential
obstacles.
The inducible system permitted selection, expansion, and
continuous culture of stable clones, while avoiding the selection
pressure expected from overexpression of a tumour suppressor.
Upon addition of Dox, functionally relevant expression of p16 in
MiaPaca-2-TREx-p16 was reproducibly obtained as judged from
the ability to downmodulate pRB (Fang et al, 1998) and to reduce
colony formation in soft agar (Plath et al, 2000), but did not block
proliferation of MiaPaca-2 cells. Thus, the system seemed well
suited for further in vivo use.
For several reasons, the orthotopic approach seemed of
particular benefit: First, primary tumours were allowed to form
and progress within their correct microenvironment. Thus, tissue-
specific interactions between tumour cells and the stromal and
vascular compartments, which are increasingly recognised as
major determinants of the tumour phenotype, were maintained
(Blouw et al, 2003; Chu et al, 2007). Second, orthotopic pancreatic
tumours metastasised using the clinically relevant route of
lymphatic metastasis and thereby offered information that is
unavailable from subcutaneous xenografts. Third, the orthotopic
approach in nude mice allowed to utilise human carcinoma cells,
which are expected to reflect the characteristic molecular makeup
of the human disease. Thus, the orthotopic model offers the
potential to obtain clinically relevant data on the effects of p16
restitution in pancreatic cancer (Killion et al, 1998).
Although a successful combination of the inducible system with
the orthotopic approach was feasible, almost one-third of the Dox-
treated tumours did not express p16 at the time of autopsy. This
may result from insufficient Dox delivery to the tumour cells or
from selection pressure to inactivate the tumour suppressor. As
these tumours may have been subjected to p16 expression for an
uncertain period of time, they had to be omitted from most
analyses. From the analyses of the remaining tumours with
confirmed p16 expression, several insights were obtained.
MiaPaca-2-TREx-p16 cells formed well vascularised orthotopic
primary tumours. This angiogenic phenotype was not correlated to
tumour size, suggesting it represented a characteristic feature of
the tumour biology of MiaPaca-2 pancreatic tumours. Dense
vascularisation was also confirmed with respect to lymph
endothelia, which have become a focus of research due to their
role in lymphatic metastasis (Stacker et al, 2002). Induction of p16
in vivo profoundly affected the angiogenic phenotype of MiaPaca-2-
TREx-p16 tumours, resulting in decreased microvessel density and
lymphatic vessel density.
The p16-mediated suppression of the angiogenic phenotype
observed here is in excellent agreement with data obtained by
inactivation of p16 in the MIN (Multiple Intestinal Neoplasia)
mouse model of colon carcinogenesis (Gibson et al, 2003, 2005).
Colonic tumours in MIN mice with additional p16 deletion
revealed a strikingly increased vascularisation and slightly larger
size as compared with p16-competent control animals. This
effect was restricted to tumours in the large intestine, suggesting
tissue-specific aspects in the regulation of angiogenesis by p16.
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Figure 5 Induction of p16 expression reduced lymphangiogenesis in orthotopic MiaPaCa-2 pancreatic carcinomas. Cryosections of the tumours were
stained with Lyve-1, an endothelial cell marker, which specifically detects lymphatic endothelia. (A) Illustration of Lyve-1 immunohistochemical detection in
representative tumours from control ( Dox) and treatment group (þDox) (images at  20 magnification). (B) Quantitative evaluation of lymphatic vessel
density (LVD) for each group (þ/ Dox). *Po0.05. (C) Missing correlation of LVD and tumour weight.
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composition of proangiogenic factors from tumour cells, stromal
cells and hypoxia (Craft and Harris, 1994). In this context, p16 was
shown to suppress VEGF-A expression in vitro (Harada et al, 1999)
and loss of p16 correlated with VEGF-A overexpression in human
oesophageal squamous cell carcinoma specimens (Takeuchi et al,
2004). However, p16 induction in MiaPaca-2-TREx-p16 cells
in vitro did not affect VEGF-A protein levels in cells or
supernatants (data not shown), suggesting p16-controlled angio-
genesis through alternate mechanisms.
One key contribution to the overall reduction of MVD was the
marked decrease of lympahtic vessel density. This experimental
link between p16 and lymphangiogenesis provides a pathobiolo-
gical concept for earlier clinical observations that associated the
loss of p16 with lymph node metastasis in several types of
carcinomas (Kawabuchi et al, 1999; Gessner et al, 2002).
Unfortunately, we could not examine this relationship in
pancreatic cancer due to the scarcity of specimens with
functionally intact p16.
Published work on lymphangiogenesis in pancreatic cancer has
identified VEGF-C and VEGF-D as important stimulators (Tang
et al, 2001; von Marschall et al, 2005) prompting us to test the
effects of p16 induction on the amount of VEGF-C or -D produced
in MiaPaca-2-TREx-p16 cells in vitro. However, neither of these
two VEGF family members were found regulated, suggesting that
additional factors controlled lymphangiogenesis in MiaPaca-2-
TREx-p16 tumours.
Irrespective of the mechanism whereby p16 reduced lymphan-
giogenesis our results strongly support the proposed sequence of
p16 induction, reduction of lymphangiogenesis, and prevention of
lymphatic metastasis in pancreatic cancer, as (i) p16 significantly
inhibited lymph node metastasis, and (ii) mice with lymph node
infiltration had significantly higher LVDs in their primary
tumours. Given the importance of lymphatic metastasis for the
clinical management of pancreatic cancer, our observations
provide an important insight into the molecular events that
determine this process. They furthermore suggest that p16 mimetic
therapies provide benefits beyond the reduction of tumour cell
proliferation and primary tumour burden.
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